Captopril

From Proteopedia
Revision as of 16:49, 28 November 2010 by David Canner (talk | contribs) (New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="Rosiglitazone/Rosiglitazon/1" align="right" caption="Rosiglitazone, also known as Avandia"/> ===Better Known as: Capot...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

Rosiglitazone, also known as Avandia

Drag the structure with the mouse to rotate

Better Known as: Capoten

  • Marketed By: Bristol-Myers Squibb
  • Major Indication: Hypertension & Congestive Heart Failure
  • Drug Class: ACE Inhibitor
  • Date of FDA Approval (Patent Expiration): 1981 (1996)
  • 2009 Sales: N/A
  • Why You Should Care: It was the first Angiotensin-Converting Enzyme Inhibitor. Was one of the earliest successes of Structure-Based drug design.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Pharmacokinetics

ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages [1][2][3][4]
Parameter Captopril Lisinopril Enalapril Benazepril
Tmax (hr)
Cmax (ng/ml)
Bioavailability (%)
Protein Binding (%) 96.7
T1/2 (hr)
AUC (ng/ml/hr)
IC50 (nM)
Equivalent Dosage (mg)
Metabolism
  1. ↑ Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. Br J Clin Pharmacol. 2008 Jan;65(1):78-86. Epub 2007 Jul 17. PMID:17635496 doi:10.1111/j.1365-2125.2007.02986.x
  2. ↑ Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant. 2009 Apr;24(4):1130-41. Epub 2008 Nov 8. PMID:18997160 doi:10.1093/ndt/gfn614
  3. ↑ Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, Haigh D, Hindley RM, Holder JC, Kallender H, Latter AJ, Lawrie KW, Mossakowska D, Murphy GJ, Roxbee Cox L, Smith SA. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9. PMID:9454824
  4. ↑ Derosa G. Pioglitazone plus glimepiride: a promising alternative in metabolic control. Int J Clin Pract Suppl. 2007 Jun;(153):28-36. PMID:17594391 doi:10.1111/j.1742-1241.2007.01362.x

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky